Celularity (CELU)

• Market cap: $90.8M
• 1 day: 1.32%
• 5 days: -7.47%
• 1 month: 29.73%
• 3 months: 61.34%
• 6 months: 164.83%
• Year to date: 74.55%
• 1 year: 27.15%
• 5 years: -96.27%
• 10 years: -96.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Employees: 123

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

56% more call options, than puts

Call options by funds: $25K | Put options by funds: $16K

14% more funds holding

Funds holding: 28 [Q1] → 32 (+4) [Q2]

13% more capital invested

Capital invested by funds: $3.43M [Q1] → $3.88M (+$449K) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0.06% less ownership

Funds ownership: 8.32% [Q1] → 8.26% (-0.06%) [Q2]

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6 56% upside
• Avg. target: $6 56% upside
• High target: $6 56% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

WBB Securities Steve Brozak

56% upside $6

Speculative Buy Initiated

18 Aug 2025